A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 07 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Sep 2018.
- 28 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2018.